| 產(chǎn)品編號 | bs-8482R |
| 英文名稱 | Rabbit Anti-CLDN7 antibody |
| 中文名稱 | 緊密連接蛋白7抗體 |
| 別 名 | CLD7_HUMAN; Claudin-7; claudin 7; CEPTRL2; CPETRL2; CLDN-7; Hs.84359; claudin-1; |
 |
Specific References (2) | bs-8482R has been referenced in 2 publications.
[IF=8.786] Ying Xiao. et al. Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by degrading tight junction protein Claudin-7.. FRONT IMMUNOL. 2022 Oct;13:1020902-1020902 IHC, WB ; Human, Mouse.
[IF=4.718] Kline KT et al. Neonatal?Injury?Increases?Gut?Permeability?by?Epigenetically?Suppressing?E-Cadherin?in?Adulthood. J Immunol. 2020 Feb 15;204(4):980-989. WB ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 細胞生物 信號轉(zhuǎn)導(dǎo) 細胞粘附分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human,Mouse,Rat,Rabbit,Sheep,Cow,Dog) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ICC/IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 22kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CLDN7: 21-100/211 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. Differential expression of this gene has been observed in different types of malignancies, including breast cancer, ovarian cancer, hepatocellular carcinomas, urinary tumors, prostate cancer, lung cancer, head and neck cancers, thyroid carcinomas, etc.. Alternatively spliced transcript variants encoding different isoforms have been found.[provided by RefSeq, May 2010] Function: Plays a major role in tight junction-specific obliteration of the intercellular space. Subunit: Directly interacts with TJP1/ZO-1, TJP2/ZO-2 and TJP3/ZO-3 (By similarity). The phosphorylated form interacts with EPCAM. Subcellular Location: Cell membrane. Lateral cell membrane. Cell junction > tight junction. Co-localizes with EPCAM at the lateral cell membrane and tight junction. Tissue Specificity: Expressed in kidney, lung and prostate. Isoform 1 seems to be predominant, except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with histological grade, occurring predominantly in high-grade lesions. Post-translational modifications: Phosphorylated. Similarity: Belongs to the claudin family. SWISS: O95471 Gene ID: 1366 Database links: Entrez Gene: 1366 Human Entrez Gene: 53624 Mouse SwissProt: O95471 Human SwissProt: Q9Z261 Mouse |
